뒤로
Minerva Neurosciences Inc(NERV) 가격
NERV 주가 차트
NERV 수입
Minerva Neurosciences Inc
$4.45
2.77%
$0.12
종가: Jan 16, 16:00:00 GMT-5
$4.34
-2.47%
$-0.11
프리마켓: Jan 20, 09:09:11 GMT-5
주요 통계
이전 종가
$4.33
시가
$4.36
일일 범위
$4.21 - $4.51
52주 범위
$1.15 - $12.46
거래량
34.9K
평균 거래량
2.1M
EPS(TTM)
-1.85
배당수익률
--
시가총액
$30.3M
NERV란 무엇인가요?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.